StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/3097% above fair value
$167.47−2.86 (-1.68%)

Close on Nov 3, 2026Market cap $207.66BP/E –Yield 1.89%

Gilead Sciences Other HCV (Sovaldi by Quarter

Other HCV (Sovaldi — legacy breakout) — Europe sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Other HCV (Sovaldi: $10M in Q4 2023, up 11.1% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2023
10
Period ended Dec 31, 2023
Change on a year earlier
+11.1%
9 in Q4 2022
History
17 quarters
Since Q4 2019
Sources
12
Documents cited below

Where the Q4 2023 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2024-02-23) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther HCV (Sovaldi — legacy breakout) — Europe sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202310+11.1%Form 10-K (filed 2024-02-23) ↗
Q3 2023Sep 30, 202370.0%Form 10-Q (filed 2023-11-07) ↗
Q2 2023Jun 30, 20239-43.7%Form 10-Q (filed 2023-08-04) ↗
Q1 2023Mar 31, 202318+125.0%Form 10-Q (filed 2023-05-03) ↗
Q4 2022Dec 31, 20229-10.0%Form 10-K (filed 2024-02-23) ↗
Q3 2022Sep 30, 20227-41.7%Form 10-Q (filed 2023-11-07) ↗
Q2 2022Jun 30, 202216+100.0%Form 10-Q (filed 2023-08-04) ↗
Q1 2022Mar 31, 20228-81.8%Form 10-Q (filed 2023-05-03) ↗
Q4 2021Dec 31, 202110-9.1%Form 10-K (filed 2024-02-23) ↗
Q3 2021Sep 30, 202112-7.7%Form 10-Q (filed 2022-11-02) ↗
Q2 2021Jun 30, 20218-11.1%Form 10-Q (filed 2022-08-08) ↗
Q1 2021Mar 31, 202144+193.3%Form 10-Q (filed 2022-05-04) ↗
Q4 2020Dec 31, 202011-38.9%Form 10-K (filed 2023-02-22) ↗
Q3 2020Sep 30, 202013–Form 10-Q (filed 2021-11-03) ↗
Q2 2020Jun 30, 20209–Form 10-Q (filed 2021-08-05) ↗
Q1 2020Mar 31, 202015–Form 10-Q (filed 2021-05-06) ↗

Cite this data

StockData. (2026). Gilead Sciences Other HCV (Sovaldi ($M), quarterly Q4 2019–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hcv-other-eu

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.

See a number that looks wrong?